BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 29945960)

  • 41. Ganetespib in Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor-resistant Non-small Cell Lung Cancer.
    Kurihara E; Shien K; Torigoe H; Takeda T; Takahashi Y; Ogoshi Y; Yoshioka T; Namba K; Sato H; Suzawa K; Yamamoto H; Soh J; Okazaki M; Shien T; Tomida S; Toyooka S
    Anticancer Res; 2019 Apr; 39(4):1767-1775. PubMed ID: 30952716
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Impaired degradation followed by enhanced recycling of epidermal growth factor receptor caused by hypo-phosphorylation of tyrosine 1045 in RBE cells.
    Gui A; Kobayashi A; Motoyama H; Kitazawa M; Takeoka M; Miyagawa S
    BMC Cancer; 2012 May; 12():179. PubMed ID: 22591401
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Polyphyllin I Overcomes EMT-Associated Resistance to Erlotinib in Lung Cancer Cells via IL-6/STAT3 Pathway Inhibition.
    Lou W; Chen Y; Zhu KY; Deng H; Wu T; Wang J
    Biol Pharm Bull; 2017 Aug; 40(8):1306-1313. PubMed ID: 28515374
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Flotillin-2 regulates epidermal growth factor receptor activation, degradation by Cbl-mediated ubiquitination, and cancer growth.
    Wisniewski DJ; Liyasova MS; Korrapati S; Zhang X; Ratnayake S; Chen Q; Gilbert SF; Catalano A; Voeller D; Meerzaman D; Guha U; Porat-Shliom N; Annunziata CM; Lipkowitz S
    J Biol Chem; 2023 Jan; 299(1):102766. PubMed ID: 36470425
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Reactivation of Mutant-EGFR Degradation through Clathrin Inhibition Overcomes Resistance to EGFR Tyrosine Kinase Inhibitors.
    Ménard L; Floc'h N; Martin MJ; Cross DAE
    Cancer Res; 2018 Jun; 78(12):3267-3279. PubMed ID: 29555874
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The E3 ubiquitin ligases RNF126 and Rabring7 regulate endosomal sorting of the epidermal growth factor receptor.
    Smith CJ; Berry DM; McGlade CJ
    J Cell Sci; 2013 Mar; 126(Pt 6):1366-80. PubMed ID: 23418353
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Phosphatase and tensin homolog deleted on chromosome 10 degradation induced by NEDD4 promotes acquired erlotinib resistance in non-small-cell lung cancer.
    Sun H; Ma H; Wang J; Xia L; Zhu G; Wang Z; Sun J; Chen Z
    Tumour Biol; 2017 Jul; 39(7):1010428317709639. PubMed ID: 28714370
    [TBL] [Abstract][Full Text] [Related]  

  • 48. An increase in BAG-1 by PD-L1 confers resistance to tyrosine kinase inhibitor in non-small cell lung cancer via persistent activation of ERK signalling.
    Lin PL; Wu TC; Wu DW; Wang L; Chen CY; Lee H
    Eur J Cancer; 2017 Nov; 85():95-105. PubMed ID: 28892778
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Lentivirus-mediated disintegrin and metalloproteinase 17 RNA interference reversed the acquired resistance to gefitinib in lung adenocarcinoma cells in vitro.
    Li YQ; Liu YS; Ying XW; Zhou HB; Wang Z; Wu SC; Yan JP; Jing YT; Yang Y
    Biotechnol Prog; 2018 Jan; 34(1):196-205. PubMed ID: 28960861
    [TBL] [Abstract][Full Text] [Related]  

  • 50. TC-N19, a novel dual inhibitor of EGFR and cMET, efficiently overcomes EGFR-TKI resistance in non-small-cell lung cancer cells.
    Wu DW; Chen TC; Huang HS; Lee H
    Cell Death Dis; 2016 Jun; 7(6):e2290. PubMed ID: 27362807
    [TBL] [Abstract][Full Text] [Related]  

  • 51. CBL is frequently altered in lung cancers: its relationship to mutations in MET and EGFR tyrosine kinases.
    Tan YH; Krishnaswamy S; Nandi S; Kanteti R; Vora S; Onel K; Hasina R; Lo FY; El-Hashani E; Cervantes G; Robinson M; Hsu HS; Kales SC; Lipkowitz S; Karrison T; Sattler M; Vokes EE; Wang YC; Salgia R
    PLoS One; 2010 Jan; 5(1):e8972. PubMed ID: 20126411
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Auranofin Enhances Ibrutinib's Anticancer Activity in EGFR-Mutant Lung Adenocarcinoma.
    Hu J; Zhang H; Cao M; Wang L; Wu S; Fang B
    Mol Cancer Ther; 2018 Oct; 17(10):2156-2163. PubMed ID: 30065099
    [TBL] [Abstract][Full Text] [Related]  

  • 53. PGE2/EP3/SRC signaling induces EGFR nuclear translocation and growth through EGFR ligands release in lung adenocarcinoma cells.
    Bazzani L; Donnini S; Finetti F; Christofori G; Ziche M
    Oncotarget; 2017 May; 8(19):31270-31287. PubMed ID: 28415726
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Induction of c-Cbl contributes to anti-cancer effects of HDAC inhibitor in lung cancer.
    Wei TT; Lin YC; Lin PH; Shih JY; Chou CW; Huang WJ; Yang YC; Hsiao PW; Chen CC
    Oncotarget; 2015 May; 6(14):12481-92. PubMed ID: 25980579
    [TBL] [Abstract][Full Text] [Related]  

  • 55. UBR-box containing protein, UBR5, is over-expressed in human lung adenocarcinoma and is a potential therapeutic target.
    Saurabh K; Shah PP; Doll MA; Siskind LJ; Beverly LJ
    BMC Cancer; 2020 Aug; 20(1):824. PubMed ID: 32867711
    [TBL] [Abstract][Full Text] [Related]  

  • 56. E3 ligase-inactivation rewires CBL interactome to elicit oncogenesis by hijacking RTK-CBL-CIN85 axis.
    Ahmed SF; Buetow L; Gabrielsen M; Lilla S; Sibbet GJ; Sumpton D; Zanivan S; Hedley A; Clark W; Huang DT
    Oncogene; 2021 Mar; 40(12):2149-2164. PubMed ID: 33627783
    [TBL] [Abstract][Full Text] [Related]  

  • 57. c-Cbl-mediated ubiquitinylation is required for epidermal growth factor receptor exit from the early endosomes.
    Ravid T; Heidinger JM; Gee P; Khan EM; Goldkorn T
    J Biol Chem; 2004 Aug; 279(35):37153-62. PubMed ID: 15210722
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Clinicopathological and genomic comparisons between different histologic components in combined small cell lung cancer and non-small cell lung cancer.
    Lin MW; Su KY; Su TJ; Chang CC; Lin JW; Lee YH; Yu SL; Chen JS; Hsieh MS
    Lung Cancer; 2018 Nov; 125():282-290. PubMed ID: 30429033
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Genome-wide DNA Methylation Analysis Reveals
    Niu X; Liu F; Zhou Y; Zhou Z; Zhou D; Wang T; Li Z; Ye X; Yu Y; Weng X; Zhang H; Ye J; Liao M; Liu Y; Chen Z; Lu S
    Clin Cancer Res; 2017 Sep; 23(17):5003-5014. PubMed ID: 28490462
    [No Abstract]   [Full Text] [Related]  

  • 60. Chloroquine in combination with aptamer-modified nanocomplexes for tumor vessel normalization and efficient erlotinib/Survivin shRNA co-delivery to overcome drug resistance in EGFR-mutated non-small cell lung cancer.
    Lv T; Li Z; Xu L; Zhang Y; Chen H; Gao Y
    Acta Biomater; 2018 Aug; 76():257-274. PubMed ID: 29960010
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.